http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Body mass index and incidence of thyroid cancer in Korea: the Korean Cancer Prevention Study-II
Shin, H. Y.,Jee, Y. H.,Cho, E. R. Springer; 1999 2017 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol.143 No.1
<P>Conclusions Our findings suggest that positive association between thyroid cancer incidence and high BMI in men and women under 50 years old. Based on these results, we suggest that obese men and women under 50 years old are better to be considered for the higher possibility of thyroid cancer development, and more efforts are needed to control weight gain.</P>
Kang, H. S.,Roh, J. L.,Kim, M. J.,Cho, K. J.,Lee, S. w.,Kim, S. B.,Choi, S. H.,Nam, S. Y.,Kim, S. Y. Springer; 1999 2016 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol.142 No.1
<P>Purpose Distant metastasis (DM) of head and neck squamous cell carcinoma (HNSCC) is not common but remains a substantial problem. Here, we evaluated factors predictive of long-term survival in HNSCC patients presenting with DM after initial definitive treatment. Methods The medical records of patients with HNSCC who underwent definitive treatment between 2006 and 2011 were reviewed. Univariate and multivariate analyses were performed to identify clinicopathological factors associated with long-term survival after DM. Results Of 779 HNSCC patients, 98 (12.6 %) had DM after completion of definitive treatment, with a median time to DM of 15 months (range 1-87 months). Overall survival (OS) rates at 1 and 2 years after DM were 43.1 and 20.5 %, respectively. In multivariate analysis, hypoalbuminemia (P < 0.001, hazard ratio [HR] 3.45, 95 % confidence interval [CI] 2.01-5.92), prior or simultaneous locoregional failure events (P < 0.001, HR 2.36, 95 % CI 1.47-3.79), multisite DM (P = 0.001, HR 2.30, 95 % CI 1.42-3.72), and no salvage treatment for DM (P = 0.003, HR 2.19, 95 % CI 1.32-3.64) were independent predictors of OS after the development of DM. Seventeen (18 %) patients survived > 2 years. Patients who did not have any of these risk factors had the most favorable outcomes, with a 2-year survival of 100 %. Conclusions In the absence of risk factors, long-term survival can be achieved despite the development of DM after definitive treatment.</P>
Ahn, Beung-Chul,Pyo, Kyoung-Ho,Xin, Chun-Feng,Jung, Dongmin,Shim, Hyo Sup,Lee, Chang Young,Park, Seong Yong,Yoon, Hong In,Hong, Min Hee,Cho, Byoung Chul,Kim, Hye Ryun Springer; 1999 2019 Journal of Cancer Research and Clinical Oncology Vol.145 No.6
<P><B>Purpose</B></P><P>Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer (NSCLC) in clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if their results represent routine clinical practice.</P><P><B>Methods</B></P><P>We examined 155 patients with advanced NSCLC who were administered either nivolumab or pembrolizumab at Yonsei Cancer Center, Korea between March 2014 and January 2019. Patient characteristics, <I>EGFR</I>/<I>ALK</I> mutation status, metastatic locations, response to ICIs, and adverse events were retrospectively analyzed.</P><P><B>Results</B></P><P>The median age was 64 years and 72.9% of patients were male; former or current smokers constituted 67.1% of the subjects. Adenocarcinoma was predominant (67.7%), and 50.3% of the patients underwent ≥ 2 previous treatments. Twenty-three patients (14.8%) were <I>EGFR</I> mutation- or <I>ALK</I> rearrangement-positive. The objective response rate (ORR) was 23.9% [95% confidence interval (CI) 17.4–31.4%]; the median progression-free survival (PFS) and overall survival (OS) were 3.06 (95% CI 1.893–4.21) and 10.25 (95% CI 5.39–15.11) months, respectively. Multivariate analysis identified ECOG performance status, <I>EGFR</I> mutation/<I>ALK</I> rearrangement status, liver metastasis and PD-L1 proportion as independent predictors of OS. Furthermore, 61.9% of the patients had adverse events of any grade; 38.1% had immune-related adverse events that were associated with PFS and OS on multivariate analysis.</P><P><B>Conclusions</B></P><P>The real-world ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials despite the patients’ different baseline characteristics. Our findings can aid in establishing effective immunotherapeutic management of NSCLC in routine clinical practice.</P><P><B>Electronic supplementary material</B></P><P>The online version of this article (10.1007/s00432-019-02899-y) contains supplementary material, which is available to authorized users.</P>